scholarly journals Preventive Administration of Non-Allergenic Bet v 1 Peptides Reduces Allergic Sensitization to Major Birch Pollen Allergen, Bet v 1

2021 ◽  
Vol 12 ◽  
Author(s):  
Oluwatoyin Akinfenwa ◽  
Huey-Jy Huang ◽  
Birgit Linhart ◽  
Margarete Focke-Tejkl ◽  
Susanne Vrtala ◽  
...  

IgE-mediated allergy to birch pollen affects more than 100 million patients world-wide. Bet v 1, a 17 kDa protein is the major allergen in birch pollen responsible for allergic rhinoconjunctivitis and asthma in birch pollen allergic patients. Allergen-specific immunotherapy (AIT) based on therapeutic administration of Bet v 1-containing vaccines is an effective treatment for birch pollen allergy but no allergen-specific forms of prevention are available. We developed a mouse model for IgE sensitization to Bet v 1 based on subcutaneous injection of aluminum-hydroxide adsorbed recombinant Bet v 1 and performed a detailed characterization of the specificities of the IgE, IgG and CD4+ T cell responses in sensitized mice using seven synthetic peptides of 31-42 amino acids length which comprised the Bet v 1 sequence and the epitopes recognized by human CD4+ T cells. We then d.emonstrate that preventive systemic administration of a mix of synthetic non-allergenic Bet v 1 peptides to 3-4 week old mice significantly reduced allergic immune responses, including IgE, IgG, IgE-mediated basophil activation, CD4+ T cell and IL-4 responses to the complete Bet v 1 allergen but not to the unrelated major grass pollen allergen Phl p 5, without inducing Bet v 1-specific allergic sensitization or adaptive immunity. Our results thus demonstrate that early preventive administration of non-allergenic synthetic T cell epitope-containing allergen peptides could be a safe strategy for the prevention of allergen-specific IgE sensitization.

2005 ◽  
Vol 116 (1) ◽  
pp. 213-219 ◽  
Author(s):  
Beatrice Jahn-Schmid ◽  
Astrid Radakovics ◽  
Dirk Lüttkopf ◽  
Stephan Scheurer ◽  
Stefan Vieths ◽  
...  

2000 ◽  
Vol 165 (11) ◽  
pp. 6653-6659 ◽  
Author(s):  
Susanne Vrtala ◽  
Cezmi A. Akdis ◽  
Ferah Budak ◽  
Mübeccel Akdis ◽  
Kurt Blaser ◽  
...  

1996 ◽  
Vol 223 (1) ◽  
pp. 187-192 ◽  
Author(s):  
Andreas J. Kungl ◽  
Markus Susani ◽  
Almut Lindemann ◽  
Mischa Machius ◽  
Antonie J.W.G. Visser ◽  
...  

1996 ◽  
Vol 183 (2) ◽  
pp. 599-609 ◽  
Author(s):  
F Ferreira ◽  
K Hirtenlehner ◽  
A Jilek ◽  
J Godnik-Cvar ◽  
H Breiteneder ◽  
...  

We dissected the T cell activation potency and the immunoglobulin (Ig) E-binding properties (allergenicity) of nine isoforms of Bet v 1 (Bet v 1a-Bet v 1l), the major birch pollen allergen. Immunoblot experiments showed that Bet v 1 isoforms differ in their ability to bind IgE from birch pollen-allergic patients. All patients tested displayed similar IgE-binding patterns toward each particular isoform. Based on these experiments, we grouped Bet v 1 isoforms in three classes: molecules with high IgE-binding activity (isoforms a, e, and j), intermediate IgE-binding (isoforms b, c, and f), and low/no IgE-binding activity (isoforms d, g, and 1). Bet v 1a, a recombinant isoform selected from a cDNA expression library using IgE immunoscreening exhibited the highest IgE-binding activity. Isoforms a, b, d, e, and 1 were chosen as representatives from the three classes for experimentation. The potency of each isoallergen to activate T lymphocytes from birch pollen-allergic patients was assayed using peripheral blood mononuclear cells, allergen-specific T cell lines, and peptide-mapped allergen-specific T cell clones. Among the patients, some displayed a broad range of T cell-recognition patterns for Bet v 1 isoforms whereas others seemed to be restricted to particular isoforms. In spite of this variability, the highest scores for T cell proliferative responses were observed with isoform d (low IgE binder), followed by b, 1, e, and a. In vivo (skin prick) tests showed that the potency of isoforms d and 1 to induce typical urticarial type 1 reactions in Bet v 1-allergic individuals was significantly lower than for isoforms a, b, and e. Taken together, our results indicate that hypoallergenic Bet v 1 isoforms are potent activators of allergen-specific T lymphocytes, and Bet v 1 isoforms with high in vitro IgE-binding activity and in vivo allergenicity can display low T cell antigenicity. Based on these findings, we propose a novel approach for immunotherapy of type I allergies: a treatment with high doses of hypoallergenic isoforms or recombinant variants of atopic allergens. We proceed on the assumption that this measure would modulate the quality of the T helper cell response to allergens in vivo. The therapy form would additionally implicate a reduced risk of anaphylactic side effects.


1995 ◽  
Vol 42 (1) ◽  
pp. 53-58 ◽  
Author(s):  
Heimo Breiteneder ◽  
Otto Scheiner ◽  
Roswitha Hajek ◽  
Wolfgang Hulla ◽  
Robert H�ttinger ◽  
...  

Vaccine ◽  
2013 ◽  
Vol 31 (46) ◽  
pp. 5405-5412 ◽  
Author(s):  
Martin Schwarzer ◽  
Dagmar Srutkova ◽  
Irma Schabussova ◽  
Tomas Hudcovic ◽  
Johnnie Akgün ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document